Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysis

Vaccine

Volumn 29, Issue 52, 2011, Pages 9711-9721

  Scott, Pippa ^a   Rutjes, Anne W S ^a,b   Bermetz, Lilian ^a   Robert, Nadège ^a   Scott, Susana ^c   Lourenço, Tania ^d   Egger, Matthias ^a   Low, Nicola ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CHIETI   (Italy)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Immunisation schedule; Meta analysis; Pneumococcal conjugate vaccine; Systematic review

Indexed keywords

ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; DOSAGE SCHEDULE COMPARISON; EUROPE; FIJI; GAMBIA; GHANA; HUMAN; ICELAND; IMMUNIZATION; IMMUNOGENICITY; ISRAEL; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY; SEROTYPE; STREPTOCOCCUS PNEUMONIA; UNITED KINGDOM;

ANTIBODIES, BACTERIAL; CARRIER STATE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; VACCINATION; VACCINES, CONJUGATE;

EID: 82555164909     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.042     Document Type: Article

References (51)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
2. Reingold A., Cutts F., Kamau T., Levine O., O'Brien K., Ignacio Santos Preciado J., et al. Detailed review paper on pneumococcal conjugate vaccine. Presented to the WHO Strategic Advisory Group of Experts (SAGE) on immunization 2006, Available from: http://www.who.int/immunization/SAGE_wg_detailedreview_pneumoVaccine.pdf [accessed August 17, 2011].
3. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180(1):48-58.
4. Andrews R., Moberley S.A. The controversy over the efficacy of pneumococcal vaccine. CMAJ 2009, 180(1):18-19.
5. Käyhty H., Nurkka A., Soininen A., Väkeväinen M. Immunological basis for immunization series. Module 12: pneumococcal vaccines 2009, Geneva: World Health Organization.
6. U.S. Food and Drug Administration (FDA). Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein). Product approval information. Available from: [accessed April 29, 2009]. http://www.fda.gov/cber/products/prevnar.htm.
7. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
8. European Medicines Agency (EMEA). Prevenar. Available from: [accessed August 17, 2011]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000323/human_med_000987.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125.
9. U.S. Food and Drug Administration (FDA). Prevnar. Available from: [accessed August 17, 2011]. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094057.htm.
10. European Medicines Agency (EMEA). Assessment report for Synflorix. Available from: [accessed August 17, 2011]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000973/human_med_001071.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125.
11. European Medicines Agency (EMEA). Prevenar 13. Available from: [accessed August 17, 2011]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/001104/human_med_001220.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d125.
12. U.S. Food and Drug Administration (FDA). Prevnar 13. Available from: [accessed August 17, 2011]. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201665.htm.
13. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007, 82(12):93-104.
14. Cutts F.T., Zaman S.M.A., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(9465):1139-1146.
15. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(14):1341-1348.
16. Trotter C.L., McVernon J., Ramsay M.E., Whitney C.G., Mulholland E.K., Goldblatt D., et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b: Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008, 26(35):4434-4445.
17. World Health Organization. WHO vaccine preventable diseases monitoring system: immunization schedules by antigen. Available from: [accessed August 17, 2011]. http://apps.who.int/immunization_monitoring/en/globalsummary/scheduleselect.cfm.
18. Juni P., Altman D.G., Egger M. Systematic reviews in health care-assessing the quality of controlled clinical trials. B.M.J 2001, 323(7303):42-46.
19. Rinta-Kokko H., Dagan R., Givon-Lavi N., Auranen K. Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine 2009, 27(29):3831-3837.
20. World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. In: Proposed replacement of TRS 927, Annex 2. Geneva: World Health Organization; 2009. Available from: [accessed August 17, 2011]. http://www.who.int/biologicals/areas/vaccines/pneumo/Pneumo_final_23APRIL_2010.pdf.
21. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., Kayhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21:3265-3272.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
23. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
24. Russell F.M., Balloch A., Tang M.L., Carapetis J.R., Licciardi P., Nelson J., et al. Immunogenicity following one: two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 2009, 27(41):5685-5691.
25. Ota M.O., Akinsola A., Townend J., Antonio M., Enwere G., Nsekpong D., et al. The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine 2011, 29(16):2999-3007.
26. Givon-Lavi N., Greenberg D., Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine A randomized controlled trial. Pediatr Infect Dis J 2010, 29:756-762.
27. Goldblatt D., Akoto O., Ashton L., Asafo-Adje E., Brainsby K., Twumasi P., et al. Immunogenicity and the generation of immune memory following 9- valent conjugate vaccination in Ghanaian infants with sickle cell disease. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2000, [Abstract no. 688].
28. Sigurdardottir S.T., Davidsdottir K., Arasonc V.A, Jonsdottir O., Laudate F., Gruberf W.C., et al. Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine 2008, 26:4178-4186.
29. Goldblatt D., Southern J., Ashton L., Richmond P., Burbidge P., Tasevska J., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006, 25(4):312-319.
30. Silfverdal S.A., Hogh B., Bergsaker M.R., Skerlikova H., Lommel P., Borys D., et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009, 28:e276-e282.
31. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(9546):1495-1502.
32. Russell F.M., Carapetis J.R., Satzke C., Tikoduadua L., Waqatakirewa L., Chandra R., et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol 2010, 17(12):1970-1976.
33. Oosterhuis-Kafeja F., Beutels P., Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007, 25(12):2194-2212.
34. Lucero M.G., Dulalia V.E., Nillos L.T., Williams G., Parreno R.A., Nohynek H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009, (4):CD004977.
35. Pavia M., Bianco A., Nobile C.G., Marinelli P., Angelillo I.F. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009, 123(6):e1103-e1110.
36. York Health Economics Consortium. Overview of evidence on pneumococcal vaccines and serotype prevalence (unpublished); 2010.
37. PneumoCarr. Streptococcus pneumoniae carriage. Available from: [cited March 24, 2011]. http://www.ktl.fi/roko/pneumocarr/index.html.
38. Goldblatt D., Southern J., Ashton L., Andrews N., Woodgate S., Burbidge P., et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J 2010, 29(5):401-405.
39. Pelton S.I., Weycker D., Klein J.O., Strutton D., Ciuryla V., Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010, 28(6):1575-1582.
40. Johnson H.L., Deloria-Knoll M., Levine O.S., Stoszek S.K., Freimanis Hance L., Reithinger R., et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010, 7(10):e1000348.
41. Williams S.R., Mernagh P.J., Lee M.H., Tan J.T. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 2011, 194(3):116-120.
42. Lehmann D., Willis J., Moore H.C., Giele C., Murphy D., Keil A.D., et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010, 50(11):1477-1486.
43. Anttila M., Eskola J., Ahman H., Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999, 17(15-16):1970-1977.
44. Nahm M.H., Olander J.V., Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis 1997, 176(3):698-703.
45. Dagan R., Givon-Lavi N., Greenberg D., Fritzell B., Siegrist C.A. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010, 201(10):1570-1579.
46. Joint Committee on Vaccination and Immunisation Proposed changes to the routine childhood immunisation schedule 2005, Available from: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_095088.pdf [accessed August 17, 2011].
47. Health Protection Agency. Pneumococcal disease. Epidemiological data. Available from: [accessed August 17, 2011]. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal.
48. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 2010, 85(43):434-436.
49. Meeting of the strategic advisory group of experts on immunization, November 2010--summary, conclusions and recommendations. Wkly Epidemiol Rec 2011, 86(1-2):1-16.
50. Altman D.G., Schulz K.F., Moher D., Egger M., Davidoff F., Elbourne D., et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134(8):663-694.
51. Wood L., Egger M., Gluud L.L., Schulz K.F., Juni P., Altman D.G., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008, 336:601-605.